文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

《SPIRIT 2025声明:随机试验方案的更新指南》

SPIRIT 2025 statement: Updated guideline for protocols of randomised trials.

作者信息

Chan An-Wen, Boutron Isabelle, Hopewell Sally, Moher David, Schulz Kenneth F, Collins Gary S, Tunn Ruth, Aggarwal Rakesh, Berkwits Michael, Berlin Jesse A, Bhandari Nita, Butcher Nancy J, Campbell Marion K, Chidebe Runcie C W, Elbourne Diana R, Farmer Andrew J, Fergusson Dean A, Golub Robert M, Goodman Steven N, Hoffmann Tammy C, Ioannidis John P A, Kahan Brennan C, Knowles Rachel L, Lamb Sarah E, Lewis Steff, Loder Elizabeth, Offringa Martin, Ravaud Philippe, Richards Dawn P, Rockhold Frank W, Schriger David L, Siegfried Nandi L, Staniszewska Sophie, Taylor Rod S, Thabane Lehana, Torgerson David J, Vohra Sunita, White Ian R, Hróbjartsson Asbjørn

机构信息

Department of Medicine, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada.

Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Centre for Research in Epidemiology and Statistics (CRESS), Paris, France.

出版信息

PLoS Med. 2025 Apr 28;22(4):e1004589. doi: 10.1371/journal.pmed.1004589. eCollection 2025 Apr.


DOI:10.1371/journal.pmed.1004589
PMID:40294521
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12037212/
Abstract

IMPORTANCE: The protocol of a randomised trial is the foundation for study planning, conduct, reporting, and external review. However, trial protocols vary in their completeness and often do not address key elements of design and conduct. The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement was first published in 2013 as guidance to improve the completeness of trial protocols. Periodic updates incorporating the latest evidence and best practices are needed to ensure that the guidance remains relevant to users. OBJECTIVE: To systematically update the SPIRIT recommendations for minimum items to address in the protocol of a randomised trial. DESIGN: We completed a scoping review and developed a project specific database of empirical and theoretical evidence to generate a list of potential changes to the SPIRIT 2013 checklist. The list was enriched with recommendations provided by lead authors of existing SPIRIT/CONSORT (Consolidated Standards of Reporting Trials) extensions (Harms, Outcomes, Non-pharmacological Treatment) and other reporting guidelines (TIDieR). The potential modifications were rated in a three-round Delphi survey followed by a consensus meeting. FINDINGS: Overall, 317 individuals participated in the Delphi consensus process and 30 experts attended the consensus meeting. The process led to the addition of two new protocol items, revision to five items, deletion/merger of five items, and integration of key items from other relevant reporting guidelines. Notable changes include a new open science section, additional emphasis on the assessment of harms and description of interventions and comparators, and a new item on how patients and the public will be involved in trial design, conduct, and reporting. The updated SPIRIT 2025 statement consists of an evidence-based checklist of 34 minimum items to address in a trial protocol, along with a diagram illustrating the schedule of enrolment, interventions, and assessments for trial participants. To facilitate implementation, we also developed an expanded version of the SPIRIT 2025 checklist and an accompanying explanation and elaboration document. CONCLUSIONS AND RELEVANCE: Widespread endorsement and adherence to the updated SPIRIT 2025 statement have the potential to enhance the transparency and completeness of trial protocols for the benefit of investigators, trial participants, patients, funders, research ethics committees, journals, trial registries, policymakers, regulators, and other reviewers.

摘要

重要性:随机试验方案是研究规划、实施、报告及外部审查的基础。然而,试验方案在完整性方面存在差异,且常常未涉及设计与实施的关键要素。《SPIRIT(标准方案项目:干预性试验建议)声明》于2013年首次发布,作为提高试验方案完整性的指南。需要定期更新以纳入最新证据和最佳实践,确保该指南对用户仍然适用。 目的:系统更新SPIRIT关于随机试验方案中应涵盖的最低项目的建议。 设计:我们完成了一项范围综述,并建立了一个针对该项目的实证和理论证据数据库,以生成对2013版SPIRIT清单的潜在修改列表。该列表通过现有SPIRIT/CONSORT(试验报告统一标准)扩展(危害、结局、非药物治疗)的主要作者及其他报告指南(TIDieR)提供的建议得到充实。在三轮德尔菲调查后,召开了一次共识会议,对潜在修改进行评分。 结果:总体而言,317人参与了德尔菲共识过程,30名专家参加了共识会议。该过程导致新增了两个方案项目,对五个项目进行了修订,删除/合并了五个项目,并整合了其他相关报告指南中的关键项目。显著变化包括一个新的开放科学部分,对危害评估以及干预措施和对照的描述给予更多强调,还有一个关于患者和公众将如何参与试验设计、实施及报告的新项目。更新后的《SPIRIT 2025声明》包括一份基于证据的清单,列出了试验方案中应涵盖的34个最低项目,以及一幅说明试验参与者入组、干预和评估时间表的图表。为便于实施,我们还制定了《SPIRIT 2025清单》的扩展版本以及一份附带的解释和详细说明文件。 结论及意义:广泛认可并遵循更新后的《SPIRIT 2025声明》,有可能提高试验方案的透明度和完整性,从而使研究者、试验参与者、患者、资助者、研究伦理委员会、期刊、试验注册机构、政策制定者、监管机构及其他审查者受益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c80d/12037212/2f4f7c0c91f7/pmed.1004589.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c80d/12037212/2f4f7c0c91f7/pmed.1004589.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c80d/12037212/2f4f7c0c91f7/pmed.1004589.g001.jpg

相似文献

[1]
SPIRIT 2025 statement: Updated guideline for protocols of randomised trials.

PLoS Med. 2025-4-28

[2]
SPIRIT 2025 statement: updated guideline for protocols of randomised trials.

BMJ. 2025-4-28

[3]
SPIRIT 2025 statement: updated guideline for protocols of randomized trials.

Nat Med. 2025-4-29

[4]
SPIRIT 2025 Statement: Updated Guideline for Protocols of Randomized Trials.

JAMA. 2025-4-28

[5]
CONSORT 2025 statement: Updated guideline for reporting randomised trials.

PLoS Med. 2025-4-14

[6]
CONSORT 2025 statement: updated guideline for reporting randomised trials.

BMJ. 2025-4-14

[7]
Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension.

JAMA. 2022-12-20

[8]
Mixed-methods study to develop extensions to the SPIRIT and CONSORT statements for factorial randomised trials: the Reporting Factorial Trials (RAFT) study.

BMJ Open. 2025-2-17

[9]
Methods used to develop the SPIRIT 2024 and CONSORT 2024 Statements.

J Clin Epidemiol. 2024-5

[10]
Guidelines for reporting pediatric and child health clinical trial protocols and reports: study protocol for SPIRIT-Children and CONSORT-Children.

Trials. 2024-1-30

引用本文的文献

[1]
A Personalized, Texting-Based Conversational Agent to Address Sleep Disturbance in Individuals Who Have Survived Breast Cancer: Protocol for a Pilot Waitlist Randomized Controlled Trial.

JMIR Res Protoc. 2025-7-14

[2]
Improving transparency in clinical trial reporting.

PLoS Med. 2025-4-28

本文引用的文献

[1]
SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials.

BMJ. 2025-4-28

[2]
CONSORT 2025 statement: Updated guideline for reporting randomised trials.

PLoS Med. 2025-4-14

[3]
Reporting summary results in clinical trial registries: updated guidance from WHO.

Lancet Glob Health. 2025-4

[4]
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants.

JAMA. 2025-1-7

[5]
Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration.

BMJ. 2024-7-9

[6]
Enhancing reporting through structure: a before and after study on the effectiveness of SPIRIT-based templates to improve the completeness of reporting of randomized controlled trial protocols.

Res Integr Peer Rev. 2024-5-31

[7]
New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance.

Ther Innov Regul Sci. 2024-5

[8]
Methods used to develop the SPIRIT 2024 and CONSORT 2024 Statements.

J Clin Epidemiol. 2024-5

[9]
Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement.

JAMA Netw Open. 2023-12-1

[10]
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.

BMJ. 2023-10-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索